Megavitamin and dietary treatment in schizophrenia: a randomised, controlled trial

References

• Vaughan K, Doyle M, McConaghy N, Blaszczynski A, Fox A, Tarrier N. The relationship between relative's expressed emotion and schizophrenic relapse: an Australian replication. Social Psychiatry and Psychiatric Epidemiology 1993; 27: 10–15
   Web of Science ®Google Scholar
• Vaughan K, Doyle M, McConaghy N, Blaszczynski A, Fox A, Tarrier N. The Sydney intervention trial: a controlled trial of relatives' counselling to reduce schizophrenic relapse. Social Psychiatry and Psychiatric Epidemiology 1993; 27: 16–21
   Web of Science ®Google Scholar
• Jorm A F, Korten A E, Jacomb P A, Christensen P A, Rodgers B. Medical Journal of Australia 1997; 166: 182–186
   PubMed Web of Science ®Google Scholar
• Pauling L. Orthomolecular psychiatry. Science 1997; 160: 265–270
   Web of Science ®Google Scholar
• Deutsch R M. The new nuts among the berries. Bull, Palo Alto, CA 1977
   Google Scholar
• Megavitamin and orthomolecular therapy in psychiatry. American Psychiatric Association, Washington, DC 1973, Task Force Report 7
   Google Scholar
• Orthomolecular psychiatry. Position Statement 24. Royal Australian and New Zealand College of Psychiatrists, Melbourne 1988
   Google Scholar
• Hoffer A. Niacin therapy in psychiatry. C.C. Thomas, Springfield, IL 1962
   Google Scholar
• Hoffer A, Osmond H. Nicotinamide Adenine Dinucleotide (NAD) as a treatment for schizophrenia. Journal of Psychopharmacology 1966; 1: 78–95
   Google Scholar
• Denson R. The value of nicotinamide in the treatment of schizophrenia. Diseases of the Nervous System 1962; 23: 167–172
   PubMedGoogle Scholar
• Whittenborn J R. Asearch for responders of niacin supplementation. Archives of General Psychiatry 1974; 31: 547–552
   PubMed Web of Science ®Google Scholar
• McGrath S D, O'Brien P F, Power P J, Shea J R. Nicotinamide treatment of schizophrenia. Schizophrenia Bulletin 1972; 5: 74–76
   Google Scholar
• Ashby W R, Collins G H, Bennet M. Effects of nicotinamide on the chronic schizophrenic. Journal of Mental Diseases 1972; 106: 1555–1559
   Google Scholar
• Ban T A, Lehmann H E. Nicotinic acid in the treatment of schizophrenics. Canadian Psychiatric Association Journal 1975; 20: 103–112
   PubMedGoogle Scholar
• Sedhev A, Harchan S, Olson J. Nicotinic acid. Comprehensive Psychiatry 1974; 15: 511–517
   PubMed Web of Science ®Google Scholar
• Ban T A, Lehman H E, Deutsch M. Negative findings with megavitamins in schizophrenic patients: preliminary report. Communications in Psychopharmacology 1977; 1: 119–122
   PubMedGoogle Scholar
• Herjanic M, Moss-Herjanic B L, Keith-Paul W. Treatment of schizophrenia with nicotinic acid. Journal of Schizophrenia 1967; 1: 197–199
   Google Scholar
• Ananth J V, Ban T A, Lehmann H E. Potentiation of therapeutic effects of nicotinic acid by pyrodoxine in chronic schizophrenics. Canadian Psychiatric Association Journal 1973; 18: 377–382
   PubMedGoogle Scholar
• Reading C M. Orthomolecular medicine and megavitamin therapy. Medical Journal of Australia 1979; 2: 40
   PubMed Web of Science ®Google Scholar
• Reading C M. Letter to the editor. Orthomolecular Psychiatry 1981; 10: 29–34
   Google Scholar
• Wing J K, Cooper J E, Sartorious N. The Description and Classification of Psychiatric Symptoms: an instruction manual for PSE and CATEGO System. Cambridge University Press, London 1974
   Google Scholar
• Derogatis L R, Melisaratos N. The Brief Symptom Inventory; an introductory report. Psychological Medicine 1983; 13: 595–605
   PubMed Web of Science ®Google Scholar
• Peterson D R. Behaviour problems in middle childhood. Journal of Consulting Psychology 1967; 25: 205–209
   Google Scholar
• Creer C, Wing J K. Schizophrenia at home. National Schizophrenia Fellowship. Surrey, Surliton 1974
   Google Scholar
• Wide I, Bennich H, Johansson S GO. Diagnosis of Allergy by an in-vitro test for allergen anti-bodies. Lancet 1967; 2: 1105–1106
   PubMed Web of Science ®Google Scholar
• Overall J E, Gorham D R. The Brief Psychiatric Rating Scale. Psychological Reports 1962; 10: 799–812
   Web of Science ®Google Scholar
• Brekke J S, Shelley L, Wolkon E S, Slade E. Psychosocial functioning and subjective experience in schizophrenia. Schizophrenia Bulletin 1993; 19: 599–608
   PubMed Web of Science ®Google Scholar
• McConaghy N, Lovibond S H. Methological formalism in psychiatric research. Journal of Nervous and Mental Diseases 1967; 144: 117–123
   PubMed Web of Science ®Google Scholar